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a  b  s  t  r  a  c  t
Skin  reactions  at the  infusion  site  are  a common  side  effect  of continuous  subcutaneous
insulin  infusion  therapy.  We  hypothesized  that  local  skin complications  are  caused  by com-
ponents of  commercial  insulin  formulations  that  contain  phenol  or m-cresol  as  excipients.
The toxic  potential  of insulin  solutions  and  the  mechanisms  leading  to skin  reactions  were
explored  in  cultured  cells.
The  toxicity  of insulin  formulations  (Apidra,  Humalog,  NovoRapid,  Insuman),  excipient-
free  insulin,  phenol  and  m-cresol  was  investigated  in  L929  cells,  human  adipocytes  and
monocytic  THP-1  cells.  The  cells  were  incubated  with  the  test  compounds  dose-  and time-
dependently.  Cell  viability,  kinase  signaling  pathways,  monocyte  activation  and  the  release
of pro-inﬂammatory  cytokines  were  analyzed.
Insulin  formulations  were  cytotoxic  in all cell-types  and  the  pure  excipients  phenol  and
m-cresol  were  toxic  to the  same  extent.  P38  and  JNK  signaling  pathways  were  activated
by  phenolic  compounds,  whereas  AKT  phosphorylation  was  attenuated.  THP-1  cells incu-
bated  with  sub-toxic  levels  of the  test  compounds  showed  increased  expression  of the
activation  markers  CD54,  CD11b  and  CD14  and  secreted  the  chemokine  MCP-1  indicating
a  pro-inﬂammatory  response.
Insulin  solutions  displayed  cytotoxic  and  pro-inﬂammatory  potential  caused  by  phenol  or
m-cresol.  We speculate  that  during  insulin  pump  therapy  phenol  and m-cresol  might  induce
cell death  and  inﬂammatory  reactions  at the  infusion  site  in  vivo.  Inﬂammation  is perpet-
uated  by  release  of MCP-1  by  activated  monocytic  cells  leading  to  enhanced  recruitment
of  inﬂammatory  cells.  To  minimize  acute  skin  complications  caused  by phenol/m-cresol
accumulation,  a  frequent  change  of infusion  sets  and  rotation  of the  infusion  site  is  recom-
mended.
© 2014  The  Authors.  Publ
the  CC  BY-NC-N
Abbreviations: APC, allophycocyanin; CCL2, chemokine ligand 2; CD,
cluster of differentiation; CSII, continuous subcutaneous insulin infusion;
DMSO, dimethyl sulfoxide; ERK, extracellular signal-regulated kinase;
IgG, immunoglobulin G; IL, interleukin; JNK, Jun N-terminal kinase;
MAP  kinase, mitogen-activated protein kinase; MCP-1, monocyte chemo-
tactic protein-1; Mip-1,  macrophage inﬂammatory protein-1alpha;
PE, phycoerythrin; TNF, tumor necrosis factor alpha; XTT, 2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide.
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1. Introduction
Patients suffering from insulin-dependent diabetes
mellitus have two  main options for insulin administra-
tion: multiple daily injections or continuous subcutaneous
insulin infusion (CSII) using insulin pumps. It is well doc-
umented that many patients beneﬁt from CSII therapy
by achieving a better glycemic control [1]. Although CSII
is a safe and efﬁcient therapy, it may  be hampered by
metabolic and non-metabolic complications. Among these
are technical problems with the infusion sets (occlusion,
is is an open access article under the CC BY-NC-ND license
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inked tubes, leakage), lipohypertrophy, and local skin
eactions at the infusion site (inﬂammation, infection, scar-
ing) [2,3]. Inﬂammation at the infusion site has high
revalence, especially among pediatric patients (25–42%)
4–6]. The occurrence of these adverse events increases
ith longer indwelling time of the insulin catheter, which
s reﬂected by the limited application time of 3–4 days
ound in clinical studies or surveys [7–10] and the fact
hat most manufacturer recommend to change the infu-
ion set every 2–3 days. Infusion sets have been optimized
o reduce skin reactions by means of material selection
nd design. Using modern infusion sets the occurrence
f true infections at the infusion site is very low com-
ared to what was seen in clinical trials in the 1980ies
11,12]. However, skin irritation and inﬂammation is a
ersistent problem for patients on CSII therapy and are
 major reason for premature catheter replacement and
ven for giving up on CSII [13,14]. However, the underly-
ng mechanism for acute skin complications has not been
esolved.
Preparations of insulin or rapid-acting insulin analogs
ontain phenolic excipients that serve two purposes: main-
aining sterility of the solution and stabilization of the
nsulin molecule in the hexameric form to avoid aggre-
ation [15,16]. All insulin formulations for pump use
ontain either phenol, m-cresol or a mixture of both
n considerable amounts (29–32 mM or 2.7–3.2 mg/ml).
hese compounds are problematic since they are known
o be toxic and irritant, and are suspected sensitizers
nd carcinogens [17,18]. There is limited knowledge on
he toxicity of insulin solutions when administered to
ubcutaneous tissue. One clinical study reported that
kin irritation at the infusion site are more common in
atients using insulin preparations with m-cresol as com-
ared to insulin containing methyl p-hydroxybenzoate
s preserving agent [19]. However, this study was con-
ucted with a small number of patients and it is not
lear if the results can be transferred to current insulin
ormulations.
The aim of the study was to investigate the toxic
otential of current pump insulins in vitro using cultured
ells. We  hypothesized that m-cresol or phenol in rele-
ant concentrations could lead to cell death and trigger
ro-inﬂammatory responses. The murine ﬁbroblastic cell
ine L929 was selected as a model, because it is a well-
stablished tool for cytotoxicity testing generating highly
eproducible results. Although not of human origin, L929
ells are commonly used for risk assessment of medical
evices like infusion catheters. This cell line was  pre-
erred for cytotoxicity testing of insulin formulations to
btain comparable results. Besides ﬁbroblasts, adipose tis-
ue mainly consists of adipocytes. Therefore, we  have
hosen human adipocytes to conﬁrm our results in a sec-
nd model that is closer to human physiology. In addition,
e tested whether phenol or m-cresol would stimulate the
ecretion of pro-inﬂammatory cytokines by immune cells.
or this purpose, human monocytic THP-1 cells were pre-
erred, as cell activation by pro-inﬂammatory stimuli as
ell as cytokine secretion can be monitored in this cell
ine.orts 2 (2015) 194–202 195
2. Materials and methods
2.1. Chemicals
Phenol (CAS No.108-95-2) and m-cresol (CAS No. 108-
39-4) were obtained from Sigma–Aldrich. Jun N-terminal
kinase (JNK) inhibitor SU3327 (10–20 M in dimethyl sulf-
oxide (DMSO)) and p38 Inhibitor SB202190 (1–2 M in
DMSO) were from Tocris Bioscience.
The following formulations of insulin or insulin analogs
were used, each at 100 I.U./ml: Apidra (3.15 mg/ml m-
cresol, Sanoﬁ-Aventis), Insuman Infusat (2.7 mg/ml  phenol,
Sanoﬁ-Aventis), Humalog (3.15 mg/ml  m-cresol, Eli Lilly),
NovoRapid (1.72 mg/ml  m-cresol and 1.5 mg/ml  phenol,
Novo Nordisk). Recombinant human insulin (Roche Diag-
nostics GmbH) was dissolved in phosphate buffer at
3 mg/ml  (equivalent to 100 U/ml).
2.2. Cell culture and viability assay
The murine ﬁbroblast cell line L929 and the human
monocytic cell line THP-1 were cultured in RPMI1640
(Sigma–Aldrich) supplemented with 10% fetal calf serum,
2 mM l-glutamine, 100 U/ml penicillin and 100 g/ml
streptomycin at 37 ◦C and 5% CO2.
Cell viability assay was performed using the Cell
Proliferation kit II (XTT) (Roche Diagnostics GmbH).
Brieﬂy, the tetrazolium salt 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) is
cleaved by viable cells to form an orange formazan dye that
can be quantiﬁed photometrically at 492 nm.  Before the
assay, 1 × 104 L929 cells were cultured in 96-well plates
for 24 h. The culture medium was  replaced by medium
containing the desired concentration of insulin solutions,
phenol or m-cresol. The cells were incubated for 24 h or
otherwise as indicated. The XTT reagent was added and
absorption was  measured after 2 h using the Synergy4 plate
reader (BioTek Instruments). Data analysis was performed
using the Gen5 Data Analysis Software (BioTek Instru-
ments). The threshold for toxicity was  set to <70% cell
viability.
2.3. Cytokine Immunoassay
5 × 105 THP-1 cells were incubated with insulin solu-
tions or phenol or m-cresol (0.2 mg/ml) for 24 h. The
release of the cytokines interleukin (IL)-1, IL-6, IL-8,
IL-12, tumor necrosis factor alpha (TNF), macrophage
inﬂammatory protein-1 alpha (Mip-1) and monocyte
chemotactic protein-1 (MCP-1) was  determined in cell-free
supernatants obtained by centrifugation. Immunodetec-
tion was  performed using cytometric bead assays (CBA, BD
Bioscience) and a BD FACSarray ﬂow cytometer (BD Bio-
science) as described by the manufacturer. Data analysis
was performed using FCAP array software v1.0.1 (Soft ﬂow
Hungary Ltd.).
2.4. CD54, CD11b and CD14 immunostainingMonocyte activation was determined by cluster of dif-
ferentiation (CD)54, CD11b and CD14 expression. THP-1
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Fig. 1. Insulin formulations are cytotoxic in L929 cells. L929 cells were exposed to different insulin solutions for 24 h. Cell viability was assessed relatively
to  culture medium control (= 100%) by XTT assay. Insulin formulations were diluted 1:3 (ﬁlled bars) or 1:10 (open bars) in culture medium. Insulin
 = 6, # p concentration was  1 or 0.3 mg/ml, respectively. Error bars indicate S.D., n
cells were incubated with insulin solutions or phenol
or m-cresol (0.2 mg/ml) for 24 h. Cells were washed and
blocked in 10% human serum and then were incubated
with phycoerythrin (PE)-labeled CD54, PE-labeled CD11b
or allophycocyanin (APC)-labeled CD14 antibodies (BD Bio-
science). Isotype controls were incubated with PE-labeled
immunoglobulin (Ig) G1 and APC-labeled IgG2a antibod-
ies (BD Bioscience). After washing cells were analyzed by
ﬂow cytometry (BD FACSArray, BD Bioscience).
2.5. Phospho-kinase array
The Proteome Proﬁler Phospho-Kinase Array kit (R + D
Systems) was used. Cell lysis and assay procedure were
performed as described by the manufacturer. A total of
600 g of protein was used in each array. Image acquisi-
tion was performed using a ChemiDoc XRS Imager (Biorad
Laboratories) and Quantity One analysis software (Biorad
Laboratories).
2.6. Western blot analysis
30–50 g protein were subjected to SDS gel elec-
trophoresis. The proteins were then transferred to PVDF
Western Blotting Membrane (Roche Diagnostics GmbH),
blocking was performed with 1% Western Blocking Reagent
(Roche Diagnostics GmbH) for 1 h. The membrane was
then incubated with the respective primary and secondary
antibodies for 1 h. After washing, Lumi-LightPlus West-
ern Blotting Substrate (Roche Diagnostics GmbH) was
added and signals were analyzed with a ChemiDoc XRS
Imager (Biorad Laboratories) and Quantity One software
(Biorad Laboratories). Antibodies used: JNK, phospho-JNK
(T183/Y185), p38, phospho-P38  (T180/Y182) from R + D
Systems; protein kinase B (AKT), phospho-AKT (S473),
anti-rabbit-horseradish peroxidase conjugate from Cell
Signaling Technology; anti--actin-peroxidase conjugate
from Sigma–Aldrich.< 0.001.
2.7. Statistics
Standard deviation is indicated by error bars. Unpaired,
two-tailed t-tests were performed and signiﬁcance was
assumed for p values less than 0.05.
3. Results
In order to test the cytotoxic potential of various insulin
formulations, L929 cells were incubated with Humalog,
Apidra, NovoRapid, Insuman, all diluted 1:3 with culture
media, or excipient-free human insulin at a concentration
of 1 mg/ml  for 24 h. The XTT test revealed that all com-
mercial insulin solutions caused a signiﬁcant drop in cell
viability below the toxicity threshold of 70%. In contrast,
insulin dissolved in medium without any excipient did not
impair cell viability (Fig. 1). Therefore it can be excluded
that cell-death was  caused by the supra-physiological
insulin concentrations used in these experiments. A 1:10
dilution of the insulin formulations did not cause toxicity
in L929 cells.
After this initial observation, we  hypothesized that the
excipients phenol and m-cresol caused the toxic effect of
insulin solutions. To test this, all low molecular weight
components were removed from different insulin for-
mulations using desalting columns. The resulting eluate
contained insulin or insulin analogs in phosphate buffer
with only trace amounts of phenol or m-cresol. The XTT test
revealed no cytotoxicity of these eluate. Upon re-addition
of phenol or m-cresol, the eluate caused cell death to the
same degree as the insulin formulations (Fig. S1). This indi-
cated that the compounds causing cytotoxicity of insulin
formulations are phenol and m-cresol. In addition, L929
cells were incubated with either pure phenol or m-cresol
in a dose dependent manner (0–2.5 mg/ml) for 24 h, which
revealed the threshold of toxicity at 0.6 mg/ml  for m-cresol.
For phenol the toxic threshold was  1.2 mg/ml indicating
that it is less toxic to the cells than m-cresol (Fig. 2).
When patients infuse insulin into subcutaneous tis-
sue, the contact time of insulin solutions with cells is
limited, since small volumes are injected into the body
C. Weber et al. / Toxicology Rep
Fig. 2. Concentration-dependent phenol and m-cresol toxicity in L929
cells. L929 cells were exposed to phenol or m-cresol in a dose dependent
manner (0.0–2.5 mg/ml) for 24 h. XTT test was  performed to analyze cell
viability in relation to culture medium control (= 100%). Phenol: triangles
and  full line; m-cresol: squares and dashed line.
Table 1
Cell viability after short-term exposure with insulin formulations.
Cell viability in % (SD)
5 min 10  min 15 min
Apidra 0.4 (0.22)# 0.0 (0.17)# 0.2 (0.16)#
Humalog 0.5 (0.62)# 0.2 (0.14)# 0.0 (0.25)#
Insuman 61.2 (5.72)# 36.2 (3.42)# 34.4 (2.68)#
NovoRapid 49.2 (4.60)# 20.9 (2.35)# 10.8 (0.80)#
Insulin 88.6 (2.21) 92.5 (2.31) 94.0 (2.26)
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mndicated time periods. The solutions were then replaced by fresh culture
edium and cell viability was  assessed after 24 h. n = 6, # p < 0.001 (versus
nsulin).
hat will be absorbed rapidly. To further analyze the toxic
otential, L929 cells were incubated with undiluted insulin
ormulations (2.7–3.2 mg/ml  phenol or m-cresol) for short
ime periods of 5, 10 or 15 min. Insulin solutions were
hen replaced by fresh cell culture medium and the cells
ere incubated for 24 h before cell viability was assessed.
n incubation of only 5 min  with undiluted insulin solu-
ions was sufﬁcient to induce cell death (Table 1). Cells
reated with Insuman for 5 min  showed 61.2% cell viability
hich declined to 34.4% after 15 min  treatment. Novo-
apid treated cells showed 49.2% viability or 10.8% viability
fter 5 min  or 15 min  treatment, respectively. Induction of
ell death was somewhat stronger in Humalog and Apidra
ig. 3. Cell viability after short-term exposure of L929 cells with phenol or m-cr
,  10 or 15 min. The supernatant was replaced by fresh culture medium and XTT 
edium control (= 100%). Error bars indicate S.D., n = 6, * p < 0.05, *** p < 0.001.orts 2 (2015) 194–202 197
treated cells (less than 1% viable cells after 5 min  treat-
ment), both of which contain m-cresol as preservative.
Incubation with excipient-free insulin only marginally
affected cell viability. Using pure phenol or m-cresol for
short term incubations the same degree of toxicity was
observed as with insulin solutions. Phenol and m-cresol
were used at a concentration of 3 mg/ml, which is equiva-
lent to the concentration in undiluted insulin preparations.
Cells treated with 3 mg/ml  of m-cresol for 5 min  were not
viable. Incubation with phenol for 5 min  resulted in 83.3%
viability which declined to 19.9% after 10 min  and 6.7% after
15 min  incubation (Fig. 3).
For cytotoxicity studies, rapidly dividing cell lines with
high metabolic activity (like L929 cells) are the preferred
model. However, we wanted to conﬁrm the toxic effects of
insulin formulations in a model that more closely resem-
bles the situation in subcutaneous tissue. Therefore, human
adipocytes were chosen as a second cell model. Human
white pre-adipocytes from subcutaneous tissue were
differentiated toward mature adipocytes. These highly dif-
ferentiated cells showed no proliferation. Adipocytes were
incubated with various concentrations (0.0–4.0 mg/ml) of
either phenol of m-cresol for 24 h. The threshold of tox-
icity was  0.9 mg/ml  for m-cresol and 2.3 mg/ml  in case of
phenol (Fig. S2). This data conﬁrmed the results obtained
with L929 cells that phenol is less toxic than m-cresol.
Adipocytes tolerated higher concentrations of the preser-
vatives compared to ﬁbroblasts, which could be explained
by their lower metabolic activity. To analyze the effects of
short-term exposure with insulin formulations, adipocytes
were incubated with undiluted insulin solutions for 10 min
which were then replaced by fresh medium for 24 h before
cell viability was  assessed. The insulin formulations caused
high levels of cell death, except for Insuman that was at
the toxicity threshold (76% cell viability) and caused higher
toxicity only when added to the cells > 15 min  (Fig. S3).
Excipient-free insulin solutions had no impact on cell via-
bility. Taken together, these data conﬁrm the toxicity of
insulin formulations after very short contact-time in a sec-
ond cell model.
To identify molecular signaling pathways affected by m-
cresol or phenol treatment, L929 cell-lysates were appliedthe relative phosphorylation levels of 43 different kinases
(Fig. 4). Compared to untreated cells, phosphorylation of
the mitogen-activated protein (MAP)-kinases p38 and JNK
esol. L929 cells were treated with 3 mg/ml phenol (a) or m-cresol (b) for
test was performed after 24 h. Cell viability is given in relation to culture
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Fig. 4. Phospho-kinase array analysis of phenol or m-cresol treated L929 cells. L929 cells were treated with 1 mg/ml phenol or m-cresol for 30 min. Cell
eated c
ean inte
ed cells.lysates were prepared and incubated with a phospho-kinase array. Untr
m-cresol-treated cells). Right: densitometric analysis of the arrays. The m
kinase  phosphorylation in phenol or m-cresol treated cells versus untreat
was signiﬁcantly induced by m-cresol, whereas extracellu-
lar signal-regulated kinase (ERK) phosphorylation was not
altered. In phenol-treated cells there was a moderate up-
regulation of p38 (2.4-fold), whereas there was no effect
on ERK or JNK. The phosphorylation of AKT was reduced by
approx. 50% in phenol or m-cresol-treated cells. The phos-
phorylation of other kinases was not signiﬁcantly altered
(Fig. 4, left panel).
These observations were conﬁrmed by Western-
blotting. Phosphorylation of p38 was strongly induced
by treatment with m-cresol for 30 min. There was  only
a slight induction of phospho-p38 in phenol-treated
cells. The amount of total p38 was unaffected (Fig. 5a).
JNK-phosphorylation was induced by treating cells with m-
cresol for 30 min. The phosphorylation was much weaker in
phenol-treated cells. Total JNK-levels remained unaltered
(Fig. 5b). Phosphorylation of AKT was reduced after 30 min
treatment with phenol or m-cresol (Fig. 5c).
We  hypothesized that, in addition to the cytotoxic
effect, phenol/m-cresol might activate immune cells,
Fig. 5. Western blot analysis of phenol or m-cresol treated L929 cells. L929 cells 
were  subjected to Western blot analysis to determine levels of (a) p38 and phos
AKT  and phospho-AKT (pAKT). -Actin served as loading control.ells served as controls. Left: images of the arrays (untreated, phenol- or
nsity of two  array spots is depicted to illustrate the relative induction of
thereby promoting an inﬂammatory response. For this
purpose the monocytic cell line THP-1 was chosen as a
model. The toxic threshold for THP-1 cells was determined
ﬁrst (>0.3 mg/ml  for m-cresol; >0.45 mg/ml  for phenol).
In the following experiments, THP-1 cells were incubated
with sub-toxic levels of phenol/m-cresol (0.2 mg/ml) to
exclude release of pro-inﬂammatory mediators from dis-
integrated cells. This is equivalent to the concentration of
phenol/m-cresol in a 1:15 dilution of commercial insulin
preparations.
As markers of inﬂammatory cell activation we explored
the expression of the cell surface proteins CD54, CD11b
and CD14. THP-1 cells were subjected to sub-toxic doses
of phenol, m-cresol or insulin solutions for 24 h. Insulin
solutions caused a 2–3-fold induction of CD11b, CD14 and
CD54 surface expression, while insulin without preserva-
tives had no effect (Fig. 6a–c). CD11b and CD54 expression
were induced 2–3-fold by phenol and m-cresol. CD14 was
induced almost 4-fold by m-cresol and 2.5-fold by phenol
(Fig. 6b). The elevated expression of CD54, CD11b and CD14
were incubated with 1 mg/ml phenol or m-cresol for 30 min. Cell lysates
pho-p38 (pp38); (b) JNK and phospho-JNK (pp54-JNK or pp46-JNK); (c)
C. Weber et al. / Toxicology Rep
Fig. 6. Expression of inﬂammatory cell-surface proteins in THP-1 cells.
THP-1 cells were incubated with different insulin solutions, phenol or m-
cresol for 24 h. Cell surface expression of (a) CD11b; (b) CD14; (c) CD54
was determined by incubation with ﬂuorophor-conjugated antibodies
and subsequent ﬂow cytometric analysis. Data is presented as relative ﬂu-
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srescence intensity compared to untreated control cells (set to 1). Error
ars indicate S.D., n = 3, # p < 0.001.
ndicated that THP-1 cells were activated by m-cresol or
henol.
Next we assessed if THP-1 activation resulted in release
f pro-inﬂammatory cytokines. The cells were incubated
ith 0.2 mg/ml  of phenol or m-cresol for 24 h and there-
fter the secretion of various pro-inﬂammatory cytokines
nto the supernatant was determined. We  did not observe
igniﬁcantly more IL-1, IL-6, IL-8, IL-12, TNF or Mip-1orts 2 (2015) 194–202 199
in treated cells as compared to untreated cells (Table S1).
In contrast, MCP-1 secretion increased from <5 pg/ml in
untreated cells up to 30–40 pg/ml in phenol and m-cresol
treated THP-1 cells (Fig. 7a). Likewise, incubating THP-1
cells with sub-toxic levels of Apidra, Humalog, NovoRapid
or Insuman resulted in signiﬁcant release of MCP-1 into the
supernatant, whereas insulin solution lacking excipients
had no effect (Fig. 7a). To analyze whether MCP-1 induc-
tion occurred on the gene transcription level, RNA was
isolated from m-cresol- or phenol-treated THP-1 cells and
cDNA was generated by reverse transcription. Real-time
PCR ampliﬁcation was used to determine expression of the
chemokine ligand 2 (ccl2) gene which codes for the MCP-
1 protein. A 10.4-fold or 11.4-fold induction of ccl2 gene
expression was observed after treatment with m-cresol or
phenol, respectively (Fig. S4).
As it is known that MCP-1 expression is regulated by
the MAP  kinases p38 and JNK in monocytes and other
cell-types [20], we tested whether speciﬁc inhibitors of
these kinases would affect MCP-1 release after m-cresol
treatment in THP-1 cells. The cells were incubated with
0.2 mg/ml  m-cresol for 24 h in the presence of the JNK
inhibitor SU3327 or the p38-inhibitor SB202190. At a con-
centration of 10 M,  the JNK inhibitor SU3327 partially
inhibited MCP-1 release from m-cresol treated cells. At a
concentration of 20 M,  MCP-1 release was  fully inhibited
(Fig. 7b). In contrast, the p38 Inhibitor SB202190 rather
increased m-cresol-induced MCP-1 release (Fig. S5). This
data indicated that m-cresol induced MCP-1 expression in
THP-1 cells via the JNK signaling pathway.
4. Discussion
We  have shown that commercial insulin solutions
have a cytotoxic potential in vitro. The toxic effect was
assessed using the ﬁbroblastic cell line L929, primary
human adipocytes and monocytic THP-1 cells. Insulin solu-
tion without excipients did not cause cell death, whereas
pure phenol or m-cresol displayed the same level of toxic-
ity as the commercial insulin formulations indicating that
they are the main cause for toxicity. Importantly, cytotox-
icity was  detected even after very short exposure-time of
only 5 min  in L929 cells and 10 min  in human adipocytes.
This emphasizes the relevance of our ﬁndings to the real
life application of phenol/m-cresol containing drugs that
are injected into the subcutaneous tissue in small vol-
umes forming a transient depot before they are absorbed.
Using cell cultures has limitations since there are important
differences between the in vitro situation and the subcuta-
neous tissue in vivo. In the culture dish, there is only one
cell-type present in a single layer. The toxic compounds
tested have direct access to the cells and the concentra-
tion will be uniform throughout the dish. In contrast, the
subcutaneous tissue is a complex three-dimensional struc-
ture consisting of various cell types (ﬁbroblasts, adipocytes,
immune cells and others), extracellular matrix as well as
lymphatics and blood vessels. The toxic compound injected
will initially form a depot. By diffusion and convection the
compound spreads in the tissue and will eventually be
absorbed via the lymphatics and the blood stream. This
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Fig. 7. MCP-1 release of THP-1 cells treated with insulin solutions, m-cresol or phenol. (a) THP-1 cells were incubated with insulin solutions, phenol or
m-cresol  for 24 h. The supernatant was collected and MCP-1 release was determined using an immunoassay (cytometric bead assay). Error bars indicate
resol or
reated oS.D.,  n = 3, * p < 0.05, *** p < 0.001. (b) THP-1 cells were incubated with m-c
supernatant was analyzed by immunoassay (cytometric bead assay). Unt
n  = 3, * p < 0.05, ** p < 0.01.
results in an anisotropic distribution of the toxic compound
and formation of concentration gradients.
Phenol and/or m-cresol are essential components of
insulin solutions and the concentrations applied by insulin
injections are considered to be save [15,18,17]. By CSII
the tissue is repetitively subjected to high local phenol/m-
cresol concentrations. There is only little information
available how this will affect the subcutaneous tissue
locally. In cultured rat liver slices the toxic effect of m-cresol
was apparent at concentrations above 5 mM (= 0.54 mg/ml)
[21], but further detailed information on cytotoxicity or
pro-inﬂammatory effects of m-cresol is lacking. The cyto-
toxicity of phenol was analyzed in several cell types
among them L929 cells, human ﬁbroblasts and keratino-
cytes [22–25]. However, short-term exposure of cells with
phenol or m-cresol was not investigated. The cytotoxic
effects of phenol may  be due to oxidation of phenolic com-
pounds to free radical intermediates known as phenoxyl
radicals [26]. It was shown that free radicals formed from
phenol are capable of inducing oxidative stress and causing
an inﬂammatory response in the skin [27]. Furthermore,
phenol induced arachidonic acid, TNF and IL-8 release
in cultured keratinocytes [23,24,28] and IL-1 in cultured
epidermal cells [27].
We have shown that the phosphorylation of MAP
kinases p38 and JNK is strongly induced by m-cresol in
L929 cells while induction by phenol is much weaker.
Both kinases have essential roles in cellular stress-signaling
[29]. P38 activation leads to upregulation and activation
of a variety of pro-inﬂammatory mediators [30]. Sus-
tained JNK activation triggers apoptosis by expression of
pro-apoptotic genes and by modulating the function of
pro- and anti-apoptotic proteins in mitochondria [31].
Additionally, phenol or m-cresol treated cells showed a
strong reduction of AKT phosphorylation. AKT is one of the
most critical pathways regulating cell survival. AKT pro-
vides pro-survival signals and blocks apoptotic stimuli by
modulating several downstream targets [32]. The strong
down-regulation of AKT phosphorylation in phenol or m-
cresol treated cells is in line with the induction of cell
death by these compounds. Collectively, these data show m-cresol + JNK inhibitor SU3327 (SU) for 24 h. Release of MCP-1 into the
r vehicle (DMSO) treated cells served as controls. Error bars indicate S.D.,
that speciﬁc signaling pathways are modulated by m-cresol
or phenol treatment. These pathways provide a molecular
mechanism explaining the patho-physiological responses
to these excipients.
In THP-1 cells, we observed upregulation of inﬂam-
matory cell surface proteins CD11b (an integrin and
receptor for complement C3), CD14 (receptor for bacte-
rial lipopolysaccharide) and the cell adhesion molecule
CD54. In line with the enhanced cell activation, we
assumed that phenol/m-cresol could enhance inﬂamma-
tory responses by triggering the release of cytokines. The
pro-inﬂammatory cytokine MCP-1 was selectively secreted
after phenol/m-cresol treatment, while several other well-
known cytokines were not secreted. So far it has not been
reported that MCP-1 is induced by phenol or m-cresol.
MCP-1 is the main factor mediating macrophage recruit-
ment to the site of injury after wounding [33]. The ccl2
gene (which codes for the MCP-1 protein) is regulated
by AP-1 transcription factors that are targets of p38 and
JNK signaling [20]. Accordingly, JNK or p38 signaling was
reported to mediate MCP-1 release in THP-1 cells and other
cell types [30,34–36].
Using the JNK-inhibitor SU3327 we clearly showed the
m-cresol induced MCP-1 release in THP-1 cells is medi-
ated via the JNK pathway. The fact that sub-toxic doses of
phenol/m-cresol activated THP-1 cells and increased MCP-
1 secretion signiﬁcantly contributes to the understanding
of local tissue reactions at the infusion sites of subcuta-
neously delivered drugs. The reason for the high prevalence
of skin irritation at the infusion site remained unknown.
We propose a model in which the insertion trauma by
the infusion needle is a ﬁrst trigger for inﬂammatory cell
recruitment. Indeed, it has been shown by insertion of
microdialysis catheters into subcutaneous adipose tissue
that within a few hours cytokines are released from the
wounded tissue [37–39]. As shown here, even short expo-
sure of phenol/m-cresol induces cell death which further
stimulates inﬂammatory and repair processes at the infu-
sion site. Additionally, phenol/m-cresol induce monocyte
activation and MCP-1 release to sustain the inﬂammatory
response. These processes will likely lead to the clinical
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